Viatris (VTRS) News Today $12.08 +0.32 (+2.72%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 12:25 PM | fool.com3 Surprisingly Underrated Stocks to Buy Right NowJuly 26 at 12:00 PM | globenewswire.comViatris Inc (VTRS:NAS) Company Profile: Analytics, Extensive Financial Metrics, and Benchmark Against Averages and Top Companies Within its IndustryJuly 25 at 1:00 AM | globenewswire.comIdorsia announces financial results for the first half 2024July 19, 2024 | msn.comBig pharma rally after J&J earningsJuly 3, 2024 | prnewswire.comViatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business DivestitureJuly 2, 2024 | reuters.comUS DOJ drops Viatris unit Mylan from industry-wide antitrust probeJuly 2, 2024 | prnewswire.comU.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust InvestigationJune 25, 2024 | prnewswire.comViatris Named to TIME's World's Most Sustainable Companies 2024 ListJune 13, 2024 | seekingalpha.comViatris: Revenues, Debt, Valuation And Strategy Under The MicroscopeJune 11, 2024 | seekingalpha.comViatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)June 7, 2024 | prnewswire.comViatris to Report Second Quarter 2024 Financial Results on August 8, 2024June 6, 2024 | seekingalpha.comViatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)June 4, 2024 | prnewswire.comViatris to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | prnewswire.comViatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of DirectorsMay 31, 2024 | prnewswire.comViatris to Participate in the Jeffries Global Healthcare ConferenceMay 30, 2024 | seekingalpha.comViatris: Skeptics Proven Right Once AgainMay 30, 2024 | marketbeat.comViatris Q1 Earnings TranscriptMay 23, 2024 | theglobeandmail.comStocks Mixed as Weekly Jobless Claims Climb to an 8-1/2 Month HighMay 21, 2024 | prnewswire.comViatris Publishes 2023 Sustainability Report: Building Sustainable Access at ScaleMay 21, 2024 | globenewswire.comIdorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigorMay 14, 2024 | seekingalpha.comViatris Inc. (VTRS) BofA Securities 2024 Health Care Conference (Transcript)May 13, 2024 | stocknews.com3 Top-Rated Pharma Stocks to Diversify Your PortfolioMay 10, 2024 | finance.yahoo.comViatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | theglobeandmail.comStocks Rise on Fed Rate Cut HopesMay 9, 2024 | investorplace.comVTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | seekingalpha.comViatris Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | reuters.comViagra maker Viatris misses revenue estimates on weak demand for older drugsMay 9, 2024 | markets.businessinsider.comViatris Inc. Q1 Profit Drops, Inline With EstimatesMay 9, 2024 | prnewswire.comViatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance RangesMay 8, 2024 | msn.comViatris Q1 Earnings Preview: Focus remains on capital allocationMay 8, 2024 | markets.businessinsider.comViatris is about to announce its earnings — here's what Wall Street expectsMay 2, 2024 | prnewswire.comViatris to Participate in the BofA Securities 2024 Health Care ConferenceMay 1, 2024 | bizjournals.comViatris partners with Unmind on mental health in the workplaceMay 1, 2024 | prnewswire.comViatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental HealthApril 24, 2024 | seekingalpha.comInflation Reduction Act: A Bullish Catalyst For Viatris Inc.April 19, 2024 | finanznachrichten.deViatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and HealthcareApril 16, 2024 | finance.yahoo.comViatris to Report First Quarter 2024 Financial Results on May 9, 2024April 15, 2024 | finanznachrichten.deViatris Inc.: Viatris Appoints Corinne Le Goff as Chief Commercial OfficerApril 15, 2024 | markets.businessinsider.comViatris Announces Launch Of Bioequivalent Generic For Copaxone In Canada - Quick FactsApril 8, 2024 | seekingalpha.comViatris Stock: Way Too Undervalued With $1 Billion Buyback PotentialApril 5, 2024 | reuters.comUK's Theramex sees no impact to HRT products supply after CMA probeApril 4, 2024 | msn.comViatris- Theramex deal for women's care products raises antitrust concerns in U.K.April 2, 2024 | benzinga.comViatris Stock (NASDAQ:VTRS), Quotes and News SummaryApril 2, 2024 | msn.comTeva and Viatris Granted Opportunity to Contest J&J’s Patent for Schizophrenia DrugApril 1, 2024 | msn.comTeva and Viatris revives chance to dispute J&J's schizophrenia drug patentApril 1, 2024 | reuters.comTeva, Viatris win new chance to challenge J&J schizophrenia drug patentApril 1, 2024 | stockhouse.comViatris Announces the Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% in the United StatesApril 1, 2024 | finance.yahoo.comViatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United StatesApril 1, 2024 | markets.businessinsider.comViatris Announces US Commercial Launch Of RYZUMVl 0.75%March 30, 2024 | seekingalpha.comViatris Stock Is Still Worth Buying Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Top Stock Unveiled! (Ad)Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. Get Your Free Report VTRS Media Mentions By Week VTRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.480.62▲Average Medical News Sentiment VTRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼53▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Takeda Pharmaceutical News Alnylam Pharmaceuticals News Teva Pharmaceutical Industries News Genmab A/S News Royalty Pharma News BioMarin Pharmaceutical News BeiGene News United Therapeutics News Sarepta Therapeutics News Dr. Reddy's Laboratories News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
